Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The Income Tax Department on Friday issued a notification allowing hospitals and nursing homes to accept cash payments of ₹2 lakh and more for the treatment of coronavirus infected patients. The Central Board of Direct Taxes (CBDT), that frames policy for the department, issued the notification. It said hospitals, dispensaries, nursing homes, COVID care centres or similar other medical facilities providing <keyword id="8918466" type="UNKNOWN" weightage="20" keywordseo="covid-19-treatment">COVID-19 treatment</keyword> to patients are being "specified for the purpose of section 269ST of the Income Tax Act". This section restricts any person from receiving an amount of ₹2 lakh or more in cash, from a person in a day, in respect of a single transaction or in respect of transactions relating to one event or occasion from a person. It was introduced by the Union government in 2017 as a measure to curb black money. The notification said the latest provision is being made for a period between April 1-May 31 "on obtaining the PAN or Aadhaar of the patient and the payee and the relationship between the patient and the payee" by such hospitals or COVID care centres. Officials said the move was aimed to remove the hardship being faced by relatives and caregivers of coronavirus infected patients who visit the hospitals for treatment. The country is grappling with the onslaught of a massive COVID-19 wave with a record over 4.14 lakh new infections and 3,915 deaths being reported in a span of 24 hours, as per the Union health ministry data updated on Friday. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/a-potentially-lethal-fungal-disease-is-creeping-into-recovering-covid-19-patients-and-the-prognosis-is-not-good/articleshow/82476375.cms">A potentially lethal fungal disease is creeping into recovering Covid-19 patients, and the prognosis is not good</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/gautam-adani-net-worth-has-crossed-60-billion-as-per-forbes/articleshow/82454659.cms">Gautam Adani’s net worth has crossed $60 billion – thanks to Adani Ports’ profits</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/good-news-for-tata-steel-jsw-steel-sail-hindalco-and-other-indian-steel-companies/articleshow/82451127.cms">China has broken another emissions record ⁠— and it is good news for some Indian companies</a>

Indian government allows cash payment of over ₹2 lakh for COVID-19 treatment at hospitals

<ul class="summary-list"><li>Many large insurers no longer waive COVID-19 treatment costs, <a href="https://www.healthsystemtracker.org/brief/most-private-insurers-are-no-longer-waiving-cost-sharing-for-covid-19-treatment/">a new analysis</a> found.</li><li>Insurers started charging again once vaccines became widely available.</li><li>But <keyword id="11916945" type="UNKNOWN" weightage="60" keywordseo="hospitalizations" source="Orion">hospitalizations</keyword> are rising in the US. Those hospitalized with COVID-19 may pay $1,300, on average.</li></ul>A year ago, around 88% of people enrolled in private health plans through their employers would have had their treatment costs waived had they gotten COVID-19.That's according to an <a href="https://www.healthsystemtracker.org/brief/cost-sharing-waivers-and-premium-relief-by-private-plans-in-response-to-covid-19/">analysis</a> from the Kaiser Family Foundation. But now, most people who get hospitalized with COVID-19 could wind up with a hefty bill. A <a href="https://www.healthsystemtracker.org/brief/most-private-insurers-are-no-longer-waiving-cost-sharing-for-covid-19-treatment/">new report</a> from the same group found that among the two largest insurers in each US state, 72% no longer waive costs for COVID-19 treatment.KFF calculated that the average patient hospitalized with pneumonia (which requires a similar treatment to COVID-19) winds up responsible for around $1,300 in out-of-pocket costs - assuming they have an employer-provided plan.The US government requires private insurers to make COVID-19 tests and vaccines free to the public, but treatments were never part of that mandate. So some states - Massachusetts, New Mexico, Idaho, Michigan, Minnesota, and Rhode Island - enacted their own requirements that insurers waive out-of-pocket treatment costs.But even in other states, private insurers have covered treatment costs during the pandemic for the most part - either as a courtesy to patients or a preemptive measure in case the federal government mandated it, KFF found.Then in November, insurers started to change course. By April 2021, roughly half of the 102 large health plans that KFF examined had stopped waiving COVID-19 treatment costs. Now, just 29 of those plans are waiving costs. Ten of those waivers are set to expire by the end of October, and another 12 will likely expire by the end of 2021.<div type="image" title="Louisiana hospital covid" height="4024" width="6048" msid="85515548" hostid="261"></div>The analysis concluded that insurers "may no longer face political or public relations pressure to continue waiving costs for COVID-19 treatment" now that vaccines are widely available.But COVID-19 hospitalizations are skyrocketing again in the US: On average, daily hospitalizations have risen seven-fold in the last two months, from around 1,600 per day to 11,700 per day. That's similar to levels recorded in February, before vaccines were widely available.Hospitals are now <a href="https://www.businessinsider.com/louisiana-hospital-capacity-failure-covid-2021-8">approaching capacity</a> in Kentucky, Louisiana, and Georgia, among several other states. Alabama has run out of ICU beds. Healthcare workers say they're delaying non-emergency surgeries and denying patient transfers. Some patients have had to wait hours to be admitted to the emergency room. If hospitals become completely full, doctors may have to start turning people away, in some cases determining who lives and who dies.The Delta variant has made severe disease more likely for unvaccinated Americans, who represent the vast majority of COVID-19 hospitalizations. The KFF analysis found that COVID-19 hospitalizations among unvaccinated people cost the US health system $2.3 billion in June and July of this year alone.

Large insurers have stopped waiving COVID-19 treatment costs, an analysis found. Hospitalization could cost you thousands.

JohnnyGreig/Getty ImagesDepending on your symptoms, coronavirus treatment costs can get into the mid-thousands.<ul class="summary-list"><li>Uninsured Americans with COVID-19 would pay an estimated average of $73,300 for a 6-day hospital stay, according to a <a href="https://s3.amazonaws.com/media2.fairhealth.org/brief/asset/COVID-19%20-%20The%20Projected%20Economic%20Impact%20of%20the%20COVID-19%20Pandemic%20on%20the%20US%20Healthcare%20System.pdf">recent report by FAIR Health</a>.</li><li>There are <a href="https://www.theguardian.com/commentisfree/2020/feb/28/coronavirus-millions-of-americans-uninsured?utm_term=Autofeed&amp;CMP=fb_us&amp;utm_medium=Social&amp;utm_source=Facebook&amp;fbclid=IwAR0SloevlMPekRwR2R80AHEAkg3sI37FaR_jYMivYXtCI2-rLqjohy8MqSc#Echobox=1582889494">27 million Americans without insurance</a>.</li><li><a href="https://www.businessinsider.com/signs-you-might-have-coronavirus-if-you-have-few-symptoms-2020-3">COVID-19 symptoms range widely</a> and treatment could vary, so costs could realistically be far less - or more.</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet">Visit Business Insider's homepage for more stories</a>.</li></ul>A trip to the hospital for coronavirus treatment <a href="https://www.businessinsider.com/how-much-does-coronavirus-treatment-cost-cdc-health-insurance-2020-2">may set you back (many) thousands</a>.<a href="https://s3.amazonaws.com/media2.fairhealth.org/brief/asset/COVID-19%20-%20The%20Projected%20Economic%20Impact%20of%20the%20COVID-19%20Pandemic%20on%20the%20US%20Healthcare%20System.pdf">A recent report</a> by healthcare cost database <a href="https://www.fairhealthconsumer.org/">FAIR Health</a>, which looked at the economic impact of the coronavirus pandemic on the healthcare system, found that a six-day inpatient stay for treatment of coronavirus symptoms would cost 100% of the price for someone without insurance: a whopping average of $73,300. (The same would apply if you stay in a hospital outside of your insurance network and your insurance plan doesn't have out-of-network benefits.) There are <a href="https://www.theguardian.com/commentisfree/2020/feb/28/coronavirus-millions-of-americans-uninsured?utm_term=Autofeed&amp;CMP=fb_us&amp;utm_medium=Social&amp;utm_source=Facebook&amp;fbclid=IwAR0SloevlMPekRwR2R80AHEAkg3sI37FaR_jYMivYXtCI2-rLqjohy8MqSc#Echobox=1582889494"> 27 million Americans without insurance</a>, despite the passage of the Affordable Care Act.The analysis considered nearly 18 million people under age 65 who used employer health plan claims.The chart below looks at the estimated average costs per patient with COVID-19, per the report. It breaks down payment costs for professionals - individual health providers like physicians - and for a six-day inpatient stay for those with and without insurance. It also includes the average reimbursement amounts for Medicare and Medicaid patients, which are $10,561 and $7,533, respectively.Andy Kiersz/Business InsiderThose with insurance are estimated to have an average medical bill for the same duration stay of $38,221, but that doesn't mean that's how much they'll pay. That is the rate negotiated between your insurance plan and your in-network health providers. How much you'd actually pay depends on your insurance plan. To determine these cost averages, Fair Health looked at the most commonly received treatment and professional services that patients with influenza and pneumonia in its sample size received. A respiratory illness, COVID-19 typically include <a href="https://www.businessinsider.com/signs-you-might-have-coronavirus-if-you-have-few-symptoms-2020-3">shortness of breath in severe cases</a>. But symptoms range widely across individuals, and treatment is often a case-by-case basis.It's possible that if you are hospitalized for COVID-19, you won't undergo all of these procedures, might undergo different procedures, or could undergo additional procedures. So, you could owe less - or more - than what's shown in the chart above, depending on your treatment.But even if you aren't hospitalized for COVID-19, testing and treatment could still cost a pretty penny. Danny Askinsi, based in the Boston area, <a href="https://time.com/5806312/coronavirus-treatment-cost/">told Time magazine</a> that she tested positive for COVID-19 and is uninsured. Her testing and treatment involved three trips to the ER before she was tested, resulting in a nearly $40,000 medical bill. And two people who didn't test positive, but received other related treatment and testing, <a href="https://www.businessinsider.com/coronavirus-treatment-costs-america-expensive-2020-3">received bills for over $3,000</a>. Add up all these high medical costs for matters of life and death during a pandemic and you see a <a href="https://www.businessinsider.com/coronavirus-treatment-costs-america-expensive-2020-3">broken healthcare system</a> at a time when Americans literally can worst afford it.Get the latest <a href="/coronavirus-covid19">coronavirus analysis and research</a> from Business Insider Intelligence on how COVID-19 is impacting businesses. <h3>NOW WATCH: <a href="https://www.businessinsider.com/how-to-stay-safe-covid-19-outbreak-2020-3">How to stay safe at work during the COVID-19 outbreak</a></h3>

If you're hospitalized with COVID-19 and don't have insurance, you'll likely owe $73,000. One chart shows how broken the system is for the most vulnerable.

Goa is in the process of updating its <keyword id="8699674" type="UNKNOWN" weightage="20" keywordseo="Home-isolation">home isolation</keyword> protocol, Health Minister Vishwajit Rane said, adding that the state government is also in the process of further revising the capping of fees for treatment of Covid-19 patients in private hospitals. "We are in the process of further improving our home isolation protocol. It will be announced by the Chief Minister soon," Rane said, after a review meeting at the Chief Minister's official residence in <keyword id="6358261" type="LOCATION" weightage="20" keywordseo="panaji">Panaji</keyword> on Tuesday. Goa currently has around 5,667 active Covid-19 cases, from which a large number of patients have opted for treatment in home isolation. Rane also said that the government was in dialogue with the private healthcare players, in order to further revise the capping of rates for treatment of Covid-19 patients in private hospitals. "We are in the process of revising the rates," Rane said, adding that despite the revision and the capping of prices, patient-to-patient costs may still vary with the nature of treatment given to the Covid-19 patients. Last week, the Goa government had capped the prices for Covid-19 treatment in private hospitals with patients availing treatment in a general ward having to pay 12,000 per day, treatment in twin-shared rooms was capped at Rs 15,000 and while fees for admission of a Covid-19 patient in a private room was set at Rs 25,000 per day. Price for utilising the ICU facilities had been capped at Rs 25,000 per day. The capped pricing, however, came under severe criticism from the <keyword id="6360456" type="COMPANY" weightage="20" keywordseo="Opposition">Opposition</keyword> as well as on social media, on which users said that the capped prices were too steep for the average wage earner in Goa. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/education/news/cbse-and-ugc-should-ensure-admission-of-students-giving-compartment-exams-says-sc/articleshow/78253213.cms">CBSE and UGC should ensure admission of students giving compartment exams, says SC</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/airline-ticket-refund-dgca-tells-sc-that-tickets-booked-during-lockdown-are-entitled-for-refund/articleshow/78251898.cms">Airline ticket refund: DGCA tells SC that tickets booked during lockdown are entitled for refund</a>

Goa to revise home isolation protocol and fees for COVID-19 treatment

New Delhi, June 15 () Apex healthcare industry body NATHEALTH on Monday said it has urged the Delhi government to mandate the hospitals to publish their treatment charges for COVID-19. In a representation to Delhi Health Minister Satyendar Kumar Jain on 'COVID Package Pricing', NATHEALTH also recommended the appointment of an ombudsman at zonal level to inspect the complaints of overcharging. The representation highlights the unprecedented challenges being faced by private healthcare providers in COVID-19 treatment, it added. "Pricing is a factor of quality of infrastructure, level of services, medical protocol followed, brands of medicines used, skill and salaries of doctors and staff and more importantly the medical outcomes," NATHEALTH said. The focus of treatment protocols in COVID-19 times has undergone a significant shift and hospitals need to equally ensure that healthcare workers are not infected while treating patients and hospitals themselves don't become hotspots, it added. This responsibility has thus led to increase in cost of care, both for COVID-19 and non-COVID-19 patients , the statement said. The private hospitals under NATHEALTH have said they fully support the need for transparency of pricing to ensure that patients are not overcharged. Equally, there is a necessity of being viable, ensuring no compromise in the quality of care and more importantly no risk to healthcare professionals, it added. AKT ANU ANU

NATHEALTH urges Delhi govt to mandate hospitals to publish COVID-19 treatment charges

<ul class="summary-list"><li>President Trump's three-day hospital stay cost much more than the treatment the average American <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> patient receives.</li><li>We estimate Trump's bill would have cost nearly $650,000 out of pocket, between experimental drug treatments, his hospital stay, and transportation.</li><li>But the actual cost extends beyond the president's own infection — the costs of treatment for people he may have infected is still unknown. </li></ul>

Trump's COVID-19 treatment would have cost an estimated $650,000 out of pocket

<ul class="summary-list"><li>The <keyword id="11899468" type="UNKNOWN" weightage="60" keywordseo="fda" source="Orion">FDA</keyword> will meet to discuss <a href="https://www.businessinsider.com/merck-asks-fda-to-authorize-covid-19-antiviral-pill-2021-10">Merck's COVID-19 pill</a> in late November, which means the treatment could get authorized in December.</li><li>The drug seems to prevent vulnerable people from requiring hospitalization or dying.</li></ul>The first-ever COVID-19 pill could be available before the end of the year.This week, <keyword id="12020331" type="UNKNOWN" weightage="60" keywordseo="merck" source="Orion">Merck</keyword> and Ridgeback Biotherapeutics asked the Food and Drug Administration (FDA) to <a href="https://www.businessinsider.com/merck-asks-fda-to-authorize-covid-19-antiviral-pill-2021-10">authorize their antiviral pill</a> for COVID-19. An FDA advisory panel will <a href="https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meeting-discuss-merck-and-ridgebacks-eua-application-covid-19-oral">meet to discuss the request</a> on November 30 - the first time such a panel has evaluated a <keyword id="11959748" type="UNKNOWN" weightage="60" keywordseo="covid-19-treatment" source="Orion">COVID-19 treatment</keyword>. (It did not hold meetings about the other COVID-19 treatments authorized so far.)If the pill meets the FDA's standards for safety and efficacy, the agency will likely greenlight the drug in December.Merck's pill was found to halve the risk of hospitalization or death among adults with mild to moderate symptoms. Just 7% of people who received the pill in a clinical trial were hospitalized or died, compared with 14% of those who got a placebo. Each of those groups contained nearly 400 people.The drug could fill a major hole for doctors looking to treat sick, unvaccinated patients - particularly as the winter threatens to drive up cases."If you can stop the virus before it makes someone very sick, then it's a game-changer," Dr. Mike Ryan, executive director of the World Health Organization's Health Emergencies Program, <a href="https://www.facebook.com/WHO/videos/215138117219233">said during a Facebook Q&amp;A</a> earlier this month.<keyword id="12216042" type="UNKNOWN" weightage="60" keywordseo="antiviral" source="Orion">Antiviral</keyword> pills, Ryan added, are the "holy grail" of treatments.Here's what to know about Merck's pill.<h2>Who will be eligible?</h2>Merck's pill, molnupiravir, probably won't be available to everyone who gets COVID-19.To participate in the company's trial, adults had to have at least one factor that put them at risk of severe COVID-19, such as obesity, diabetes, heart disease, or being over age 60. Participants also started the treatment within five days of developing symptoms, so those who have been sick for longer than that may not be eligible.Merck's trial also looked exclusively at unvaccinated people, so it's not yet known whether the treatment will be recommended for those who get breakthrough cases after getting vaccinated.<h2>Why is a COVID-19 pill necessary?</h2>So far, the FDA has fully approved just one treatment for COVID-19: the antiviral remdesivir, which is administered via injection. That drug has been found to <a href="https://www.nejm.org/doi/full/10.1056/nejmoa2007764">shorten recovery time</a> for hospitalized patients, but it's not a treatment for mild or moderate COVID-19.The FDA also authorized the emergency use of <a href="https://www.businessinsider.com/tennessee-vaccinated-denied-monoclonal-antibody-treatment-2021-9">monoclonal antibodies</a>, drugs that help keep people with mild or moderate symptoms from developing severe COVID-19. These come in two forms, infusions or injections - both of which are administered at hospitals or clinics. Though monoclonal antibodies are free to the public, they can cost the government <a href="https://www.npr.org/sections/health-shots/2020/10/28/928841997/government-signs-deal-for-covid-19-treatments-from-eli-lilly">more than $2,000 per dose</a>.So drugmakers have been working to develop cheaper, less invasive treatments.Merck's fits the bill: The drug would cost the government around $700 per treatment (though it would also be free to Americans). That full regimen consists of 40 pills - four capsules twice a day for five days. The drug will likely be available as a prescription at pharmacies.But it's not a replacement for vaccines, which still offer the highest chance of avoiding hospitalization or death.<div type="image" title="Capsules of molnupiravir, an antiviral drug developed by Merck and Ridgeback Biotherapeutics that could treat COVID-19" height="2002" width="3000" msid="86974087" hostid="261"></div><h2>Will the pill be easy to get?</h2>The US government has purchased enough of Merck's pill to treat 1.7 million people, and the company already started manufacturing the drug. Merck hopes to produce 10 million treatment courses by the end of the year, much of which would go to other countries.Merck has signed licensing deals with Indian manufacturers to help deliver the drug to most low- and middle-income countries, assuming the pill gets authorized in those places. The company plans to vary the price of the treatment by country.<h2>How does the pill work inside the body?</h2>Merck's pill belongs to a class of antiviral drugs called nucleosides, which can block a virus from replicating inside cells. This particular drug creates mutations in the part of its genetic code that the virus uses to replicate. Once enough of its code is changed, the virus dies out, preventing a patient's symptoms from getting worse."The virus essentially mutates itself to death," Richard Plemper, a virologist at Georgia State University, recently <a href="https://www.nature.com/articles/d41586-021-02783-1">told Nature</a>.<h2>Are there any side effects?</h2>People in Merck's trial reported a similar number of side effects regardless of whether they got the real drug or a placebo (40% of placebo recipients had side effects, compared with 35% of those who got the pill)."We're very comfortable that the drug will be safe if used as intended," Daria Hazuda, Merck's vice president of infectious diseases discovery, said in a press call earlier this month.This story has been updated with new information. It was originally published October 12.

The FDA could authorize the first COVID-19 pill in December - here's who may be eligible

<ul class="summary-list"><li>Orders for doses of <keyword id="12126602" type="UNKNOWN" weightage="60" keywordseo="monoclonal-antibodies" source="Orion">monoclonal antibodies</keyword> jumped from 27,000 in July to 168,000 doses per week in late August.</li><li>Kentucky Gov. Andy Beshear said Thursday that the state is running low on the <keyword id="11993316" type="UNKNOWN" weightage="60" keywordseo="treatment" source="Orion">treatment</keyword>.</li><li>Monoclonal antibody treatment for <keyword id="11893994" type="UNKNOWN" weightage="60" keywordseo="covid-19" source="Orion">COVID-19</keyword> received FDA authorization in 2020.</li></ul>70% of orders placed for doses of monoclonal antibodies came from seven <keyword id="12126603" type="UNKNOWN" weightage="60" keywordseo="southern" source="Orion">Southern</keyword> states, where governors frequently promote the costly treatment as part of their COVID-19 strategy, <a href="https://www.nytimes.com/2021/09/18/health/covid-antibody-regeneron.html">according to The New York Times</a>.As orders jumped from 27,000 in July to 168,000 doses per week in late August, the Biden administration told states to prepare for the nation's dwindling supply of the treatment and expect scaled-back shipments as a result of increasing demand from less-vaccinated Southern states, <a href="https://www.nytimes.com/2021/09/18/health/covid-antibody-regeneron.html">the Times reported</a>.Several states, including Missouri, Texas, and Florida, have expanded access to monoclonal antibody treatment in recent weeks, despite each of their governors opposing <keyword id="11894310" type="UNKNOWN" weightage="60" keywordseo="vaccine" source="Orion">vaccine</keyword> and mask mandates."We're going to be at a point, within a week, where there are going to be folks that want and probably need this treatment and we're not going to have enough of it," Kentucky Gov. Andy Beshear said Thursday, <a href="https://www.wlwt.com/article/what-are-monoclonal-antibodies-kentucky-in-short-supply/37631676#">according to WLWT</a>.Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful antigens such as viruses, <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19">according to the Food and Drug Administration (FDA)</a>. The treatment, which is no less experimental than COVID-19 vaccines, <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19">received FDA authorization in 2020</a>.

You Searched For "covid19 treatment cost" and got 8 results

Indian government allows cash payment of over ₹2 lakh for COVID-19 treatment at hospitals

PTI

Large insurers have stopped waiving COVID-19 treatment costs, an analysis found. Hospitalization could cost you thousands.

Aria Bendix

If you're hospitalized with COVID-19 and don't have insurance, you'll likely owe $73,000. One chart shows how broken the system is for the most vulnerable.

Hillary Hoffower

Goa to revise home isolation protocol and fees for COVID-19 treatment

IANS

NATHEALTH urges Delhi govt to mandate hospitals to publish COVID-19 treatment charges

PTI

Trump's COVID-19 treatment would have cost an estimated $650,000 out of pocket

Daniel T. Allen,Meg Teckman-F…

The FDA could authorize the first COVID-19 pill in December - here's who may be eligible

Aria Bendix

Seven Southern states account for 70% of US orders for monoclonal antibodies, the treatment of choice for many vaccine refusers

Morgan Keith

Popular Keywords

Buying Guides